| Predicted Trait | |
| Reported Trait | Venous thromboembolism |
| Mapped Trait(s) | venous thromboembolism (EFO_0004286) |
| Score Construction | |
| PGS Name | PRS273_VTE |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | imputed variants |
| Variants | |
| Original Genome Build | NR |
| Number of Variants | 273 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000449 |
| Citation (link to publication) | Folsom AR et al. PLoS One (2023) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 88.7% African: 7.9% Hispanic or Latin American: 3.4% 650,119 individuals (100%) |
| PGS Evaluation | African: 50% European: 50% 2 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST009097 Europe PMC: 31676865 |
576,590 individuals | European | NR |
GWAS Catalog: GCST009097 Europe PMC: 31676865 |
51,661 individuals | African American or Afro-Caribbean | NR |
GWAS Catalog: GCST009097 Europe PMC: 31676865 |
21,868 individuals | Hispanic or Latin American | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM017257 | PSS010177| African Ancestry| 2,484 individuals |
PGP000449 | Folsom AR et al. PLoS One (2023) |
Reported Trait: Total venous thromboembolism | — | — | Hazard ratio (HR, high vs low tertile): 1.35 [0.81, 2.25] | Adjusted for age, sex, principal components of ancestry, hormone replacement therapy (current, former, never for women, with men as referent category), education level (<high school, high school grad, >high school grad), household income (<$12,000, $12,000 to $24,999, $25,000 to $49,999, $50,000+, missing), height (continuous), weight (continuous), estimated glomerular filtration rate (continuous), diabetes (yes defined as >126 mg/dL, medication or physician diagnosis; no), smoking status (current, former, never), sports physical activity level (continuous), systolic blood pressure (continuous), antihypertensive medication use (yes, no) | — |
| PPM017256 | PSS010178| European Ancestry| 8,808 individuals |
PGP000449 | Folsom AR et al. PLoS One (2023) |
Reported Trait: Total venous thromboembolism | — | — | Hazard ratio (HR, high vs low tertile): 2.52 [1.99, 3.2] | Adjusted for age, sex, principal components of ancestry, hormone replacement therapy (current, former, never for women, with men as referent category), education level (<high school, high school grad, >high school grad), household income (<$12,000, $12,000 to $24,999, $25,000 to $49,999, $50,000+, missing), height (continuous), weight (continuous), estimated glomerular filtration rate (continuous), diabetes (yes defined as >126 mg/dL, medication or physician diagnosis; no), smoking status (current, former, never), sports physical activity level (continuous), systolic blood pressure (continuous), antihypertensive medication use (yes, no) | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS010178 | — | Median = 28.0 years | 8,808 individuals | — | European | — | ARIC | — |
| PSS010177 | — | Median = 28.0 years | 2,484 individuals | — | African unspecified | — | ARIC | — |